Apollo Endosurgery, Inc. (APEN)
APEN Price and Sentiment
APEN Latest news
Apollo Endosurgery Announces Closing of Public Offering and Exercise in Full of Option to Purchase Additional Shares
2021-10-15 16:05AUSTIN, TX / ACCESSWIRE / October 15, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, announced today the closing of its previously announced underwritten public offering. Apollo sold 9,660,000 shares of its common stock, including 1,260,000 shares sold pursuant to the underwriters' exercise in full of their option to purchase additional shares, at a public offering price of $7.75 per share for gross proceeds of approximately $75 million, before deducting underwriting discounts and commissions and offering expenses.
Apollo Endosurgery Announces Pricing of $65 Million Public Offering of Common Stock
2021-10-12 23:40AUSTIN, TX / ACCESSWIRE / October 12, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, announced today the pricing of its previously announced underwritten public offering. Apollo is selling 8,400,000 shares of its common stock at a public offering price of $7.75 per share for gross proceeds of approximately $65 million, before deducting underwriting discounts and commissions and offering expenses.
Apollo Endosurgery Announces Commencement of Public Offering of Common Stock
2021-10-12 16:01AUSTIN, TX / ACCESSWIRE / October 12, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, announced today that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the common stock is being offered by Apollo.
Apollo Endosurgery Announces Preliminary Third Quarter 2021 Financial Results and Provides Business Updates
2021-10-07 16:05Revenue expected between $16.0 million and $16.4 million Third consecutive quarter of double-digit revenue growth; endoscopic suturing up over 30% Submitted a De Novo 510(k) Classification Request to FDA for Apollo ESG™ for weight loss and Apollo REVISE™ for prior bariatric surgery revisions Principal investigators expected to present primary efficacy and safety endpoints from MERIT study in late October AUSTIN, TX / ACCESSWIRE / October 7, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, announced today preliminary unaudited financial results and corporate updates for the third quarter ended September 30, 2021, including anticipated revenue in the range of $16.0 million to $16.4 million and anticipated revenue growth in the range of 25% to 28% compared to third quarter 2020. Preliminary, Unaudited Third Quarter 2021 Financial Results Total revenue $16.0 million to $16.4 million Gross margin 54% to 56% Ope
Apollo Endosurgery to Present at Lake Street's 5th Annual Best Ideas Growth Conference
2021-09-13 08:00AUSTIN, TX / ACCESSWIRE / September 13, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced that its management team will participate in Lake Street's 5th Annual Best Ideas Growth Conference. September 14-15, 2021 Lake Street's 5th Annual Best Ideas Growth Conference Management teams from over 100 dynamic small-cap publicly traded companies will interact with over 300 institutional investors in a one-on-one conference format.
APEN Stock Price Increases Over 7% Pre-Market: Why It Happened
2021-08-04 09:19The stock price of Apollo Endosurgery, Inc. (Nasdaq:APEN) increased by over 7% pre-market. This is why it happened.
Apollo Endosurgery, Inc. (APEN) CEO Chas McCallen on Q2 2021 Results - Earnings Call Transcript
2021-08-03 22:54Apollo Endosurgery, Inc. (APEN) CEO Chas McCallen on Q2 2021 Results - Earnings Call Transcript
Apollo Endosurgery, Inc. (APEN) Reports Q2 Loss, Tops Revenue Estimates
2021-08-03 21:21Apollo Endosurgery, Inc. (APEN) delivered earnings and revenue surprises of 35.29% and 17.14%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Apollo Endosurgery, Inc. Reports Record Endoscopy Revenue in Second Quarter, Raises Full-Year Outlook Conference Call to Discuss Results Today at 3:30 p.m. CT / 4:30 p.m.
2021-08-03 16:01AUSTIN, TX / ACCESSWIRE / August 3, 2021 / Apollo Endosurgery, Inc. ("Apollo") (Nasdaq:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced financial results for the second quarter ended June 30, 2021. Highlights Achieved total revenue of $16.6 million, an increase of 194% compared to the second quarter of 2020, and a new revenue record for the Company* Increased Endoscopic Suturing System (ESS) revenue 23% and Intragastric Balloon (IGB) revenue 16% on a sequential basis compared to the first quarter of 2021 Realized gross margin of 55% on favorable product mix Continued rollout of X-Tack™ with now more than 120 active sites, demonstrating excellent product performance, a short learning curve, and utility in a diverse range of upper and lower GI applications Reported that the Multi-Center ESG Randomized Interventional Trial (MERIT) study investigators announced successful achievement of the study's primary efficacy and safety endpoints Strength
Will Apollo Endosurgery, Inc. (APEN) Report Negative Q2 Earnings? What You Should Know
2021-07-27 16:07Apollo Endosurgery, Inc. (APEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.